Phase I Clinical Trial of CA-4948 (Emavusertib) in Combination With FOLFOX Plus Bevacizumab as Frontline Treatment in Patients With Metastatic Colorectal Cancer
Latest Information Update: 25 Nov 2024
Price :
$35 *
At a glance
- Drugs Emavusertib (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Colorectal cancer
- Focus Adverse reactions
- 25 Nov 2024 New trial record